Listed in the December 27, 2023 extract; not in the current extract (Aug 26, 2026): Eltroxin (02213230). Source: odb-formulary-ed43-extract-2023-12-27.xml; compared with odb-formulary-ed43-extract-2026-08-26.xml.
LEVOTHYROXINE (SODIUM)
22 general benefit · 2 not a benefit
Other products in the same Health Canada class (H03AA) — coverage varies; not interchangeable
- Liothyronine (Cytomel): not a benefit
Apo-Levothyroxine · DIN 02550709 · 0.025mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Apo-Levothyroxine · DIN 02550709
Manufacturer: Apotex Inc.; listing date 2025-04-30
Health Canada: Marketed since 2025-03-17 · brand APO-LEVOTHYROXINE · ATC H03AA01 LEVOTHYROXINE SODIUM · form Tablet · route Oral · ingredients LEVOTHYROXINE SODIUM 25 MCG · company Apotex inc · schedule Prescription
Apo-Levothyroxine: Formulary list price $0.0597/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.0597 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103949 · Verify on the e-Formulary ↗ (DIN 02550709)
Source record
DIN 02550709: Apo-Levothyroxine
Raw flags: sec3=Y
Item: 683600016; group id 805; item number 1970; lccId None; manufacturer id APX
Source form: Tab; strength: 0.025mg
Recorded listing: General benefit
Source prices (unrounded): $0.0597; ministry $0.0597
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02550709
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103949
Interchangeable products
Synthroid · DIN 02172062 · $0.0597
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02550709
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Synthroid · DIN 02172062 · 0.025mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Synthroid · DIN 02172062
Manufacturer: Abbott Laboratories Limited; listing date 1996-10-01
Health Canada: Marketed since 2016-03-18 · brand SYNTHROID · ATC H03AA01 LEVOTHYROXINE SODIUM · form Tablet · route Oral · ingredients LEVOTHYROXINE SODIUM 25 MCG · company Bgp pharma ulc · schedule Prescription
Ministry pays: $0.0597 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19588 · Verify on the e-Formulary ↗ (DIN 02172062)
Source record
DIN 02172062: Synthroid
Raw flags: sec3=Y
Item: 683600016; group id 805; item number 1970; lccId None; manufacturer id ABB
Source form: Tab; strength: 0.025mg
Recorded listing: General benefit
Source prices (unrounded): $0.1153; ministry $0.0597
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02172062
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19588
Interchangeable products
Apo-Levothyroxine · DIN 02550709 · $0.0597
Shortage status: avoided shortage; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02172062
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Apo-Levothyroxine · DIN 02550717 · 0.05mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Apo-Levothyroxine · DIN 02550717
Manufacturer: Apotex Inc.; listing date 2025-04-30
Health Canada: Marketed since 2025-03-17 · brand APO-LEVOTHYROXINE · ATC H03AA01 LEVOTHYROXINE SODIUM · form Tablet · route Oral · ingredients LEVOTHYROXINE SODIUM 50 MCG · company Apotex inc · schedule Prescription
Apo-Levothyroxine: Formulary list price $0.0373/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.0373 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103950 · Verify on the e-Formulary ↗ (DIN 02550717)
Source record
DIN 02550717: Apo-Levothyroxine
Raw flags: sec3=Y
Item: 683600004; group id 805; item number 1971; lccId None; manufacturer id APX
Source form: Tab; strength: 0.05mg
Recorded listing: General benefit
Source prices (unrounded): $0.0373; ministry $0.0373
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02550717
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103950
Interchangeable products
Eltroxin · DIN 02213192 · $0.0373
Synthroid · DIN 02172070 · $0.0373
Shortage status: resolved shortage (ended 2025-11-13); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02550717
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Eltroxin · DIN 02213192 · 0.05mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Eltroxin · DIN 02213192
Manufacturer: Aspen Pharma Trading Limited; listing date 1997-07-12
Health Canada: Marketed since 2018-03-15 · brand ELTROXIN · ATC H03AA01 LEVOTHYROXINE SODIUM · form Tablet · route Oral · ingredients LEVOTHYROXINE SODIUM 50 MCG · company Aspen pharmacare canada inc. · schedule Prescription
Eltroxin: Formulary list price $0.0373/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.0373 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=36945 · Verify on the e-Formulary ↗ (DIN 02213192)
Source record
DIN 02213192: Eltroxin
Raw flags: sec3=Y
Item: 683600004; group id 805; item number 1971; lccId None; manufacturer id ASN
Source form: Tab; strength: 0.05mg
Recorded listing: General benefit
Source prices (unrounded): $0.0373; ministry $0.0373
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02213192
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=36945
Interchangeable products
Apo-Levothyroxine · DIN 02550717 · $0.0373
Synthroid · DIN 02172070 · $0.0373
Shortage status: resolved shortage (ended 2025-07-03); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02213192
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Synthroid · DIN 02172070 · 0.05mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Synthroid · DIN 02172070
Manufacturer: Abbott Laboratories Limited; listing date 1996-10-01
Health Canada: Marketed since 2016-03-10 · brand SYNTHROID · ATC H03AA01 LEVOTHYROXINE SODIUM · form Tablet · route Oral · ingredients LEVOTHYROXINE SODIUM 50 MCG · company Bgp pharma ulc · schedule Prescription
Ministry pays: $0.0373 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19587 · Verify on the e-Formulary ↗ (DIN 02172070)
Source record
DIN 02172070: Synthroid
Raw flags: sec3=Y
Item: 683600004; group id 805; item number 1971; lccId None; manufacturer id ABB
Source form: Tab; strength: 0.05mg
Recorded listing: General benefit
Source prices (unrounded): $0.0792; ministry $0.0373
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02172070
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19587
Interchangeable products
Apo-Levothyroxine · DIN 02550717 · $0.0373
Eltroxin · DIN 02213192 · $0.0373
Shortage status: resolved shortage (ended 2021-01-20); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02172070
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Apo-Levothyroxine · DIN 02550725 · 0.075mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Apo-Levothyroxine · DIN 02550725
Manufacturer: Apotex Inc.; listing date 2025-04-30
Health Canada: Marketed since 2025-03-07 · brand APO-LEVOTHYROXINE · ATC H03AA01 LEVOTHYROXINE SODIUM · form Tablet · route Oral · ingredients LEVOTHYROXINE SODIUM 75 MCG · company Apotex inc · schedule Prescription
Apo-Levothyroxine: Formulary list price $0.0646/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.0646 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103951 · Verify on the e-Formulary ↗ (DIN 02550725)
Source record
DIN 02550725: Apo-Levothyroxine
Raw flags: sec3=Y
Item: 683600017; group id 805; item number 1972; lccId None; manufacturer id APX
Source form: Tab; strength: 0.075mg
Recorded listing: General benefit
Source prices (unrounded): $0.0646; ministry $0.0646
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02550725
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103951
Interchangeable products
Synthroid · DIN 02172089 · $0.0646
Shortage status: resolved shortage (ended 2025-10-15); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02550725
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Synthroid · DIN 02172089 · 0.075mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Synthroid · DIN 02172089
Manufacturer: Abbott Laboratories Limited; listing date 1996-10-01
Health Canada: Marketed since 2016-03-10 · brand SYNTHROID · ATC H03AA01 LEVOTHYROXINE SODIUM · form Tablet · route Oral · ingredients LEVOTHYROXINE SODIUM 75 MCG · company Bgp pharma ulc · schedule Prescription
Ministry pays: $0.0646 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19595 · Verify on the e-Formulary ↗ (DIN 02172089)
Source record
DIN 02172089: Synthroid
Raw flags: sec3=Y
Item: 683600017; group id 805; item number 1972; lccId None; manufacturer id ABB
Source form: Tab; strength: 0.075mg
Recorded listing: General benefit
Source prices (unrounded): $0.1247; ministry $0.0646
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02172089
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19595
Interchangeable products
Apo-Levothyroxine · DIN 02550725 · $0.0646
Shortage status: resolved shortage (ended 2021-03-29); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02172089
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Apo-Levothyroxine · DIN 02550733 · 0.088mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Apo-Levothyroxine · DIN 02550733
Manufacturer: Apotex Inc.; listing date 2025-04-30
Health Canada: Marketed since 2025-03-17 · brand APO-LEVOTHYROXINE · ATC H03AA01 LEVOTHYROXINE SODIUM · form Tablet · route Oral · ingredients LEVOTHYROXINE SODIUM 88 MCG · company Apotex inc · schedule Prescription
Apo-Levothyroxine: Formulary list price $0.0646/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.0646 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103952 · Verify on the e-Formulary ↗ (DIN 02550733)
Source record
DIN 02550733: Apo-Levothyroxine
Raw flags: sec3=Y
Item: 683600024; group id 805; item number 1973; lccId None; manufacturer id APX
Source form: Tab; strength: 0.088mg
Recorded listing: General benefit
Source prices (unrounded): $0.0646; ministry $0.0646
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02550733
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103952
Interchangeable products
Synthroid · DIN 02172097 · $0.0646
Shortage status: resolved shortage (ended 2025-10-30); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02550733
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Synthroid · DIN 02172097 · 0.088mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Synthroid · DIN 02172097
Manufacturer: Abbott Laboratories Limited; listing date 1996-12-19
Health Canada: Marketed since 2016-04-20 · brand SYNTHROID · ATC H03AA01 LEVOTHYROXINE SODIUM · form Tablet · route Oral · ingredients LEVOTHYROXINE SODIUM 88 MCG · company Bgp pharma ulc · schedule Prescription
Ministry pays: $0.0646 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19599 · Verify on the e-Formulary ↗ (DIN 02172097)
Source record
DIN 02172097: Synthroid
Raw flags: sec3=Y
Item: 683600024; group id 805; item number 1973; lccId None; manufacturer id ABB
Source form: Tab; strength: 0.088mg
Recorded listing: General benefit
Source prices (unrounded): $0.1247; ministry $0.0646
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02172097
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19599
Interchangeable products
Apo-Levothyroxine · DIN 02550733 · $0.0646
Shortage status: resolved shortage (ended 2020-12-08); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02172097
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Apo-Levothyroxine · DIN 02534681 · 0.1mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Apo-Levothyroxine · DIN 02534681
Manufacturer: Apotex Inc.; listing date 2025-04-30
Health Canada: Marketed since 2025-03-17 · brand APO-LEVOTHYROXINE · ATC H03AA01 LEVOTHYROXINE SODIUM · form Tablet · route Oral · ingredients LEVOTHYROXINE SODIUM 100 MCG · company Apotex inc · schedule Prescription
Apo-Levothyroxine: Formulary list price $0.0460/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.0460 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102359 · Verify on the e-Formulary ↗ (DIN 02534681)
Source record
DIN 02534681: Apo-Levothyroxine
Raw flags: sec3=Y
Item: 683600003; group id 805; item number 1974; lccId None; manufacturer id APX
Source form: Tab; strength: 0.1mg
Recorded listing: General benefit
Source prices (unrounded): $0.0460; ministry $0.0460
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02534681
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102359
Interchangeable products
Eltroxin · DIN 02213206 · $0.0460
Synthroid · DIN 02172100 · $0.0460
Shortage status: resolved shortage (ended 2025-10-15); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02534681
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Eltroxin · DIN 02213206 · 0.1mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Eltroxin · DIN 02213206
Manufacturer: Aspen Pharma Trading Limited; listing date 1997-07-12
Health Canada: Marketed since 2018-04-06 · brand ELTROXIN · ATC H03AA01 LEVOTHYROXINE SODIUM · form Tablet · route Oral · ingredients LEVOTHYROXINE SODIUM 100 MCG · company Aspen pharmacare canada inc. · schedule Prescription
Eltroxin: Formulary list price $0.0460/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.0460 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=36946 · Verify on the e-Formulary ↗ (DIN 02213206)
Source record
DIN 02213206: Eltroxin
Raw flags: sec3=Y
Item: 683600003; group id 805; item number 1974; lccId None; manufacturer id ASN
Source form: Tab; strength: 0.1mg
Recorded listing: General benefit
Source prices (unrounded): $0.0460; ministry $0.0460
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02213206
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=36946
Interchangeable products
Apo-Levothyroxine · DIN 02534681 · $0.0460
Synthroid · DIN 02172100 · $0.0460
Shortage status: resolved shortage (ended 2025-09-15); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02213206
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Synthroid · DIN 02172100 · 0.1mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Synthroid · DIN 02172100
Manufacturer: Abbott Laboratories Limited; listing date 1996-10-01
Health Canada: Marketed since 2016-03-17 · brand SYNTHROID · ATC H03AA01 LEVOTHYROXINE SODIUM · form Tablet · route Oral · ingredients LEVOTHYROXINE SODIUM 100 MCG · company Bgp pharma ulc · schedule Prescription
Ministry pays: $0.0460 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19601 · Verify on the e-Formulary ↗ (DIN 02172100)
Source record
DIN 02172100: Synthroid
Raw flags: sec3=Y
Item: 683600003; group id 805; item number 1974; lccId None; manufacturer id ABB
Source form: Tab; strength: 0.1mg
Recorded listing: General benefit
Source prices (unrounded): $0.0977; ministry $0.0460
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02172100
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19601
Interchangeable products
Apo-Levothyroxine · DIN 02534681 · $0.0460
Eltroxin · DIN 02213206 · $0.0460
Shortage status: avoided shortage; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02172100
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Apo-Levothyroxine · DIN 02550741 · 0.112mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Apo-Levothyroxine · DIN 02550741
Manufacturer: Apotex Inc.; listing date 2025-04-30
Health Canada: Marketed since 2025-03-17 · brand APO-LEVOTHYROXINE · ATC H03AA01 LEVOTHYROXINE SODIUM · form Tablet · route Oral · ingredients LEVOTHYROXINE SODIUM 112 MCG · company Apotex inc · schedule Prescription
Apo-Levothyroxine: Formulary list price $0.0682/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.0682 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103953 · Verify on the e-Formulary ↗ (DIN 02550741)
Source record
DIN 02550741: Apo-Levothyroxine
Raw flags: sec3=Y
Item: 683600018; group id 805; item number 1975; lccId None; manufacturer id APX
Source form: Tab; strength: 0.112mg
Recorded listing: General benefit
Source prices (unrounded): $0.0682; ministry $0.0682
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02550741
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103953
Interchangeable products
Synthroid · DIN 02171228 · $0.0682
Shortage status: shortage reported ended 2026-05-08 (report last updated 2026-05-08); confirm supply with the pharmacy; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02550741
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Synthroid · DIN 02171228 · 0.112mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Synthroid · DIN 02171228
Manufacturer: Abbott Laboratories Limited; listing date 1996-10-01
Health Canada: Marketed since 2016-03-18 · brand SYNTHROID · ATC H03AA01 LEVOTHYROXINE SODIUM · form Tablet · route Oral · ingredients LEVOTHYROXINE SODIUM 112 MCG · company Bgp pharma ulc · schedule Prescription
Ministry pays: $0.0682 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19589 · Verify on the e-Formulary ↗ (DIN 02171228)
Source record
DIN 02171228: Synthroid
Raw flags: sec3=Y
Item: 683600018; group id 805; item number 1975; lccId None; manufacturer id ABB
Source form: Tab; strength: 0.112mg
Recorded listing: General benefit
Source prices (unrounded): $0.1317; ministry $0.0682
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02171228
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19589
Interchangeable products
Apo-Levothyroxine · DIN 02550741 · $0.0682
Shortage status: resolved shortage (ended 2021-02-23); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02171228
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Apo-Levothyroxine · DIN 02550768 · 0.125mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Apo-Levothyroxine · DIN 02550768
Manufacturer: Apotex Inc.; listing date 2025-04-30
Health Canada: Marketed since 2025-03-17 · brand APO-LEVOTHYROXINE · ATC H03AA01 LEVOTHYROXINE SODIUM · form Tablet · route Oral · ingredients LEVOTHYROXINE SODIUM 125 MCG · company Apotex inc · schedule Prescription
Apo-Levothyroxine: Formulary list price $0.0690/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.0690 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103954 · Verify on the e-Formulary ↗ (DIN 02550768)
Source record
DIN 02550768: Apo-Levothyroxine
Raw flags: sec3=Y
Item: 683600019; group id 805; item number 1976; lccId None; manufacturer id APX
Source form: Tab; strength: 0.125mg
Recorded listing: General benefit
Source prices (unrounded): $0.0690; ministry $0.0690
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02550768
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103954
Interchangeable products
Synthroid · DIN 02172119 · $0.0690
Shortage status: resolved shortage (ended 2025-10-30); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02550768
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Synthroid · DIN 02172119 · 0.125mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Synthroid · DIN 02172119
Manufacturer: Abbott Laboratories Limited; listing date 1996-10-01
Health Canada: Marketed since 2016-03-18 · brand SYNTHROID · ATC H03AA01 LEVOTHYROXINE SODIUM · form Tablet · route Oral · ingredients LEVOTHYROXINE SODIUM 125 MCG · company Bgp pharma ulc · schedule Prescription
Ministry pays: $0.0690 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19594 · Verify on the e-Formulary ↗ (DIN 02172119)
Source record
DIN 02172119: Synthroid
Raw flags: sec3=Y
Item: 683600019; group id 805; item number 1976; lccId None; manufacturer id ABB
Source form: Tab; strength: 0.125mg
Recorded listing: General benefit
Source prices (unrounded): $0.1333; ministry $0.0690
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02172119
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19594
Interchangeable products
Apo-Levothyroxine · DIN 02550768 · $0.0690
Shortage status: resolved shortage (ended 2021-03-02); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02172119
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Apo-Levothyroxine · DIN 02550784 · 0.15mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Apo-Levothyroxine · DIN 02550784
Manufacturer: Apotex Inc.; listing date 2025-04-30
Health Canada: Marketed since 2025-03-17 · brand APO-LEVOTHYROXINE · ATC H03AA01 LEVOTHYROXINE SODIUM · form Tablet · route Oral · ingredients LEVOTHYROXINE SODIUM 150 MCG · company Apotex inc · schedule Prescription
Apo-Levothyroxine: Formulary list price $0.0495/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.0495 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103956 · Verify on the e-Formulary ↗ (DIN 02550784)
Source record
DIN 02550784: Apo-Levothyroxine
Raw flags: sec3=Y
Item: 683600011; group id 805; item number 1977; lccId None; manufacturer id APX
Source form: Tab; strength: 0.15mg
Recorded listing: General benefit
Source prices (unrounded): $0.0495; ministry $0.0495
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02550784
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103956
Interchangeable products
Eltroxin · DIN 02213214 · $0.0495
Synthroid · DIN 02172127 · $0.0495
Shortage status: resolved shortage (ended 2025-10-09); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02550784
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Eltroxin · DIN 02213214 · 0.15mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Eltroxin · DIN 02213214
Manufacturer: Aspen Pharma Trading Limited; listing date 1997-01-20
Health Canada: Marketed since 2018-04-06 · brand ELTROXIN · ATC H03AA01 LEVOTHYROXINE SODIUM · form Tablet · route Oral · ingredients LEVOTHYROXINE SODIUM 150 MCG · company Aspen pharmacare canada inc. · schedule Prescription
Eltroxin: Formulary list price $0.0495/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.0495 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=36947 · Verify on the e-Formulary ↗ (DIN 02213214)
Source record
DIN 02213214: Eltroxin
Raw flags: sec3=Y
Item: 683600011; group id 805; item number 1977; lccId None; manufacturer id ASN
Source form: Tab; strength: 0.15mg
Recorded listing: General benefit
Source prices (unrounded): $0.0495; ministry $0.0495
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02213214
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=36947
Interchangeable products
Apo-Levothyroxine · DIN 02550784 · $0.0495
Synthroid · DIN 02172127 · $0.0495
Shortage status: resolved shortage (ended 2018-09-17); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02213214
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Synthroid · DIN 02172127 · 0.15mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Synthroid · DIN 02172127
Manufacturer: Abbott Laboratories Limited; listing date 1996-10-01
Health Canada: Marketed since 2016-03-10 · brand SYNTHROID · ATC H03AA01 LEVOTHYROXINE SODIUM · form Tablet · route Oral · ingredients LEVOTHYROXINE SODIUM 150 MCG · company Bgp pharma ulc · schedule Prescription
Ministry pays: $0.0495 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19598 · Verify on the e-Formulary ↗ (DIN 02172127)
Source record
DIN 02172127: Synthroid
Raw flags: sec3=Y
Item: 683600011; group id 805; item number 1977; lccId None; manufacturer id ABB
Source form: Tab; strength: 0.15mg
Recorded listing: General benefit
Source prices (unrounded): $0.1051; ministry $0.0495
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02172127
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19598
Interchangeable products
Apo-Levothyroxine · DIN 02550784 · $0.0495
Eltroxin · DIN 02213214 · $0.0495
Shortage status: avoided shortage; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02172127
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Apo-Levothyroxine · DIN 02550792 · 0.175mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Apo-Levothyroxine · DIN 02550792
Manufacturer: Apotex Inc.; listing date 2025-04-30
Health Canada: Marketed since 2025-03-17 · brand APO-LEVOTHYROXINE · ATC H03AA01 LEVOTHYROXINE SODIUM · form Tablet · route Oral · ingredients LEVOTHYROXINE SODIUM 175 MCG · company Apotex inc · schedule Prescription
Apo-Levothyroxine: Formulary list price $0.0740/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.0740 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103957 · Verify on the e-Formulary ↗ (DIN 02550792)
Source record
DIN 02550792: Apo-Levothyroxine
Raw flags: sec3=Y
Item: 683600020; group id 805; item number 1978; lccId None; manufacturer id APX
Source form: Tab; strength: 0.175mg
Recorded listing: General benefit
Source prices (unrounded): $0.0740; ministry $0.0740
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02550792
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103957
Interchangeable products
Synthroid · DIN 02172135 · $0.0740
Shortage status: resolved shortage (ended 2025-08-21); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02550792
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Synthroid · DIN 02172135 · 0.175mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Synthroid · DIN 02172135
Manufacturer: Abbott Laboratories Limited; listing date 1996-10-01
Health Canada: Marketed since 2016-03-17 · brand SYNTHROID · ATC H03AA01 LEVOTHYROXINE SODIUM · form Tablet · route Oral · ingredients LEVOTHYROXINE SODIUM 175 MCG · company Bgp pharma ulc · schedule Prescription
Ministry pays: $0.0740 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19600 · Verify on the e-Formulary ↗ (DIN 02172135)
Source record
DIN 02172135: Synthroid
Raw flags: sec3=Y
Item: 683600020; group id 805; item number 1978; lccId None; manufacturer id ABB
Source form: Tab; strength: 0.175mg
Recorded listing: General benefit
Source prices (unrounded): $0.1429; ministry $0.0740
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02172135
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19600
Interchangeable products
Apo-Levothyroxine · DIN 02550792 · $0.0740
Shortage status: resolved shortage (ended 2020-11-02); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02172135
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Apo-Levothyroxine · DIN 02550806 · 0.2mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Apo-Levothyroxine · DIN 02550806
Manufacturer: Apotex Inc.; listing date 2025-04-30
Health Canada: Marketed since 2025-03-17 · brand APO-LEVOTHYROXINE · ATC H03AA01 LEVOTHYROXINE SODIUM · form Tablet · route Oral · ingredients LEVOTHYROXINE SODIUM 200 MCG · company Apotex inc · schedule Prescription
Apo-Levothyroxine: Formulary list price $0.0526/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.0526 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103958 · Verify on the e-Formulary ↗ (DIN 02550806)
Source record
DIN 02550806: Apo-Levothyroxine
Raw flags: sec3=Y
Item: 683600002; group id 805; item number 1979; lccId None; manufacturer id APX
Source form: Tab; strength: 0.2mg
Recorded listing: General benefit
Source prices (unrounded): $0.0526; ministry $0.0526
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02550806
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103958
Interchangeable products
Eltroxin · DIN 02213222 · $0.0526
Synthroid · DIN 02172143 · $0.0526
Shortage status: resolved shortage (ended 2026-01-15); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02550806
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Apo-Levothyroxine · DIN 02550776 · 0.137mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Apo-Levothyroxine · DIN 02550776
Manufacturer: Apotex Inc.; listing date 2025-04-30
Health Canada: Marketed since 2025-03-17 · brand APO-LEVOTHYROXINE · ATC H03AA01 LEVOTHYROXINE SODIUM · form Tablet · route Oral · ingredients LEVOTHYROXINE SODIUM 137 MCG · company Apotex inc · schedule Prescription
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103955 · Verify on the e-Formulary ↗ (DIN 02550776)
Source record
DIN 02550776: Apo-Levothyroxine
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 683600031; group id 805; item number 1969; lccId None; manufacturer id APX
Source form: Tab; strength: 0.137mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $0.1906; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02550776
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103955
Interchangeable products
Synthroid · DIN 02233852 · not recorded
Shortage status: resolved shortage (ended 2025-10-30); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02550776
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Synthroid · DIN 02233852 · 0.137mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Synthroid · DIN 02233852
Manufacturer: BGP Pharma ULC; listing date 2025-04-30
Health Canada: Marketed since 2016-03-10 · brand SYNTHROID · ATC H03AA01 LEVOTHYROXINE SODIUM · form Tablet · route Oral · ingredients LEVOTHYROXINE SODIUM 137 MCG · company Bgp pharma ulc · schedule Prescription
Synthroid: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=53868 · Verify on the e-Formulary ↗ (DIN 02233852)
Source record
DIN 02233852: Synthroid
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 683600031; group id 805; item number 1969; lccId None; manufacturer id BGP
Source form: Tab; strength: 0.137mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02233852
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=53868
Interchangeable products
Apo-Levothyroxine · DIN 02550776 · not recorded
Shortage status: resolved shortage (ended 2021-01-20); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02233852
Shortage record checked 2026-09-13T08:10:21.292534+00:00